2020
PET Imaging of Synaptic Vesicle Protein 2A
Finnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.ChaptersSynaptic vesicle protein 2APositron emission tomographyAntiepileptic drug levetiracetamInitial PET studiesPET imagingPET studiesSynaptic densityDrug levetiracetamHigh-affinity SV2A ligandsBrain regionsSynaptic density lossNeuropathological diseasesDisease-modifying therapiesLarge patient cohortMajor depressive disorderProtein 2APET imaging resultsPosttraumatic stress disorderPatient groupPatient cohortDepressive disorderClinical valueParkinson's diseaseEfficacy assessmentSynaptic vesicle proteins
2010
Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management
Chen MK, Doddamane I, Cheng DW. Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management. Current Opinion In Oncology 2010, 22: 6-10. PMID: 19844179, DOI: 10.1097/cco.0b013e3283339d5d.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRecombinant human thyroid-stimulating hormoneHuman thyroid-stimulating hormoneMetastatic thyroid cancerThyroid-stimulating hormoneThyroid cancerThyroglobulin levelsWhole body radiation exposureThyroid hormone withdrawalThyroid remnant ablationFurther prospective studiesLong-term outcomesRate of recurrenceSurveillance of patientsThyroid cancer managementBody radiation exposureNegative predictive valueRadioiodine ablationPersistent diseaseRadioiodine treatmentRemnant ablationThyroid remnantsWithdrawal patientsPatients' qualityPatient groupProspective study